Presentation, pp.85-86, 2020
Background
The clinical course of COVID-19, which is our
global problem, is variable. Advanced age,
hypertension, diabetes, chronic lung disease,
asthma, chronic kidney diseases, liver
diseases, cancer, obesity and tobacco use
are risk groups. In the course of COVID-19,
severe pneumonia ranging from
asymptomatic patients to ARDS can be seen.
It is estimated that the average time from
the onset of symptoms to the development
of acute respiratory distress syndrome
(ARDS) is 8 days, during this time, pulse
oximetry monitoring is recommended for
patients in the risk group.
Aim
O2 is a widely used and highly
recommended therapy in China. However,
asymptomatic or mild COVID-19 has not
been adequately considered in the current
guidelines. Shen et al. in his work; He
reported that O2 supplementation can
impair virus replication, improve antiviral
immune response, reduce ACE 2 expression,
and especially nighttime O2 therapy can
delay the progression of COVID-19.